EGFR and neoplasm: Predictive biomarkers include activating mutations in EGFR, BRAF, KRASG12C, and ERBB2, rearrangements in ALK, ROS1, RET, and NTRK, MET amplification or exon 14 skipping mutations, PD-L1 expression, and tumor mutational burden.